L
Lindy G. Durrant
Researcher at University of Nottingham
Publications - 200
Citations - 6412
Lindy G. Durrant is an academic researcher from University of Nottingham. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 43, co-authored 189 publications receiving 5789 citations. Previous affiliations of Lindy G. Durrant include BioCity Nottingham & Nottingham University Hospitals NHS Trust.
Papers
More filters
Journal ArticleDOI
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.
Nicholas F S Watson,Judith M. Ramage,Zahra Madjd,Ian Spendlove,Ian O. Ellis,John H. Scholefield,Lindy G. Durrant +6 more
TL;DR: It is shown that both high levels of MHC class I expression and absent MHCclass I expression are associated with similar disease‐specific survival times, and tumors with low level expression of M HC class I were found to confer a significantly poorer prognosis, retaining independent significance on multivariate analysis.
Journal ArticleDOI
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?
Ekaterina S. Jordanova,Arko Gorter,Ouissam Ayachi,Frans J. Prins,Lindy G. Durrant,Gemma G. Kenter,Sjoerd H. van der Burg,Gert Jan Fleuren +7 more
TL;DR: A patient group with the poorest survival in cervical cancer is revealed, as a single variable, low CD8+/Treg ratio was a significant independent unfavorable prognostic factor.
Journal ArticleDOI
NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
Roger McGilvray,Robert A. Eagle,Nicholas F S Watson,Ahmad Al-Attar,Graham Ball,Insiya Jafferji,John Trowsdale,Lindy G. Durrant +7 more
TL;DR: The combination of MIC and tumor-node-metastasis stage was found to be the strongest predictor of survival, splitting patients into eight groups and suggesting prognostic value in clinical assessment.
Journal ArticleDOI
Defining the critical hurdles in cancer immunotherapy
Bernard A. Fox,Bernard A. Fox,Dolores J. Schendel,Lisa H. Butterfield,Steinar Aamdal,James P. Allison,James P. Allison,Paolo A. Ascierto,Michael B. Atkins,Jirina Bartunkova,Lothar Bergmann,Neil L. Berinstein,Cristina Bonorino,Ernest C. Borden,Jonathan L. Bramson,Cedrik M. Britten,Xuetao Cao,Xuetao Cao,William E. Carson,Alfred E. Chang,Dainius Characiejus,A. Raja Choudhury,George Coukos,Tanja D. de Gruijl,Robert O. Dillman,Harry Dolstra,Glenn Dranoff,Lindy G. Durrant,James H. Finke,Jérôme Galon,Jared Gollob,Cécile Gouttefangeas,Fabio Grizzi,Michele Guida,Leif Håkansson,Kristen Hege,Kristen Hege,Ronald B. Herberman,F. Stephen Hodi,Axel Hoos,Christoph Huber,Patrick Hwu,Kohzoh Imai,Elizabeth M. Jaffee,Sylvia Janetzki,Carl H. June,Pawel Kalinski,Howard L. Kaufman,Koji Kawakami,Yutaka Kawakami,Ulrich Keilholtz,Samir N. Khleif,Rolf Kiessling,Beatrix Kotlan,Guido Kroemer,Réjean Lapointe,Hyam I. Levitsky,Michael T. Lotze,Cristina Maccalli,Michele Maio,Jens Peter Marschner,Michael J. Mastrangelo,Giuseppe Masucci,Ignacio Melero,C. J. M. Melief,William J. Murphy,Brad H. Nelson,Andrea Nicolini,Michael I. Nishimura,Kunle Odunsi,Pamela S. Ohashi,Jill O'Donnell-Tormey,Lloyd J. Old,Christian H. Ottensmeier,Michael Papamichail,Giorgio Parmiani,Graham Pawelec,Enrico Proietti,Shukui Qin,Robert C. Rees,Antoni Ribas,Ruggero Ridolfi,Gerd Ritter,Gerd Ritter,Licia Rivoltini,Pedro Romero,Mohamed L. Salem,Rik J. Scheper,Barbara Seliger,Padmanee Sharma,Hiroshi Shiku,Harpreet Singh-Jasuja,Wenru Song,Per thor Straten,Hideaki Tahara,Zhigang Tian,Zhigang Tian,Sjoerd H. van der Burg,Paul von Hoegen,Ena Wang,Marij J. P. Welters,Hauke Winter,Tara Withington,Jedd D. Wolchok,Weihua Xiao,Laurence Zitvogel,Heinz Zwierzina,Francesco M. Marincola,Thomas F. Gajewski,Jon M. Wigginton,Mary L. Disis +110 more
TL;DR: The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report.
Journal ArticleDOI
Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
Nicholas F S Watson,Nicholas F S Watson,Ian Spendlove,Zahra Madjd,Roger McGilvray,Andrew R. Green,Ian O. Ellis,John H. Scholefield,Lindy G. Durrant +8 more
TL;DR: Patients with low levels of MICA and a poor prognosis may be good candidates for aggressive chemotherapy, as they should be susceptible to NK killing by antibody dependent cellular cytotoxicity, and patients with high expression of Mica may be candidates for the antibody therapies.